BIOHIT OYJ STOCK EXCHANGE RELEASE ON 30 SEPTEMBER 2010 AT 2:00 PM CHANGES IN BIOHIT OYJ'S DIAGNOSTICS MANAGEMENT TEAM The Diagnostics Management Team of Biohit Oyj will be reorganized in line with the new strategy of the Group. The change comes into effect on October 1st 2010. In addition to the Group's President & CEO, Mr Jussi Heiniö and the General Director of Diagnostics, Mr Yrjö Wichmann, the new Management Team will include the following members and functions: Ms Lea Paloheimo (Product Portfolio Management); Mr Kalle Härkönen (Operations); Ms Terhi Lampén (Sales and Marketing); Mr Seppo Riikonen (Quality and Risk Management); Ms Tiina Hankonen (Finance, ICT and HR); and Ms Josefin Hoviniemi (Communications). The reform reflects the new approach to make the business planning and operations more efficient and develop the company's business in a truly international direction, by utilising the Group's own resources and large network of subsidiaries. Biohit has two Management Teams. The Diagnostics Management Team focuses on the diagnostics business and its development, while the Liquid Handling Management Team focuses on the liquid handling business and its development, as well as Group-level administration. The Liquid Handling Management Team was reorganized in beginning of July this year. Jussi Heiniö President & CEO Biohit Oyj Further information: Jussi Heiniö Tel: +358-9-773 861 Email: jussi.heinio@biohit.com Distribution: NASDAQ OMX Helsinki Oy Central storage facility (www.oam.fi) Press www.biohit.com About Biohit Oyj Established in 1988, Biohit Oyj is a Finnish biotechnology company, acting on the global market. Biohit's operations are based on a goal-oriented and long-term innovation and patenting strategy. Biohit works with scientific communities to produce new technologies, products and services based on research results and innovations that can be used to develop safe and cost-effective liquid handling solutions for laboratory work as well as diagnostic tests for the early detection and prevention of diseases of the gastrointestinal tract. Biohit has two business segments: liquid handling and diagnostics. Liquid handling products include electronic and mechanical pipettes, disposable tips as well as pipette maintenance and calibration services for research institutions, healthcare and industrial laboratories. The diagnostics business comprises products and analysis systems for the early diagnosis of gastrointestinal diseases, such as the blood-sample based GastroPanel examinations for the diagnosis of stomach illnesses and associated risks, quick tests for the diagnosis of lactose intolerance and H. pylori infection in connection with gastroscopy, and the ColonView examination for the early detection of intestinal bleeding that indicates a risk of colorectal cancer. The Acetium innovation reduces carcinogenic acetaldehyde in anacidic stomachs. The Biohit Group employs around 390 people. The company is headquartered in Helsinki, Finland, and has subsidiaries in France, Germany, the UK, Russia, India, China, Japan and the USA, as well as a representative office in Singapore. Additionally, Biohit's products are sold by approximately 450 distributors in 70 countries. Biohit's series B share (BIOBV) is quoted on NASDAQ OMX Helsinki, Small cap/Healthcare since 1999. Read more at www.biohit.com